Devpro Biopharma News Today

Cystetic Medicines, Inc., a clinical-stage biotechnology company developing small molecule channels that serve as molecular prosthetics for missing or dysfunctional CFTR protein channels, announced today that the first healthy volunteer has been dosed with CM001 in a Phase 1 clinical trial. CM001 is a molecular prosthetic intended to treat people with cystic fibrosis (CF).

This observational retrospective analysis of prospectively collected data examines whether airway mucus plugs identified on chest computed tomography were assoc

These 2 randomized clinical trials compare the efficacy and safety of 2 doses of the autotaxin inhibitor ziritaxestat vs placebo in patients with idiopathic pul